Progressive Corporation
PGR
$227.52
-0.11%
Progressive Corporation is the largest publicly traded U.S. auto insurer by policies in force, underwriting private and commercial auto coverage plus specialty lines and a smaller homeowners book, with roughly 27 million personal auto policies split between the direct channel and independent agents. Its competitive identity is built on a data-driven, direct-to-consumer underwriting machine and the 'Snapshot' telematics program, which have historically delivered a structural loss-ratio advantage over peers and consistent share gains from agency carriers. The current investor debate centers on whether the multi-year margin expansion cycle has peaked: after several years of aggressive rate increases that drove combined ratios to unusually strong levels, revenue growth has decelerated to roughly 3% year over year in Q3 2026, and the market is now weighing whether underwriting margins can hold as rate increases moderate against a growing investment-income contribution from a float approaching $94 billion. Bulls point to the durability of the underwriting franchise and rising interest income; bears focus on premium growth normalization, competitive pricing pressure in auto, and the stock's premium valuation relative to its own history.…
PGR
Progressive Corporation
$227.52
Related headlines
Investment Opinion: Should I buy PGR Today?
Rating: Hold. Progressive is a genuinely best-in-class underwriter — 37.29% ROE, $15.22 billion of trailing free cash flow, a $94 billion float, and debt-to-equity of just 0.227 — but at $227.77 the stock already reflects that quality, with the 21-analyst consensus average target of $231.71 implying only +1.7% upside and 15 of 21 analysts sitting at Hold. The core thesis is that PGR is a high-quality compounder in the late innings of an exceptional underwriting margin cycle, where the earnings base is normalizing faster than the multiple is cheapening.
The supporting evidence is mixed but tilts toward patience rather than accumulation. On valuation, the 11.81x trailing PE sits near the low end of a historical band that ran from the high-teens to 58x in Q2 2023, and the 0.35 PEG looks cheap — but the 14.03x forward PE exceeding the trailing multiple means the market explicitly expects earnings to decline, and consensus EPS of $16.04 against a $227.77 price leaves little cushion. Growth has decelerated to 2.98% YoY in Q3 2026 with sequential revenue falling from $23.62 billion to $23.18 billion, while net margin compressed from 14.02% in Q2 to 10.97% in Q3 and operating margin from 17.82% to 13.96%. Offsetting this, the 4.40x P/B is defensible against a 37.29% ROE versus the ~1.5-2.0x typical for large-cap P&C peers, and $15.22 billion of trailing FCF plus $4.40 billion in Q3 alone funds both growth and the $7.97 billion Q1 special dividend plus $471 million of Q3 buybacks.
The biggest risks that could invalidate the thesis are a continued slide in personal auto underwriting margins (personal lines are $19.35 billion of Q3's $23.18 billion revenue, so a pricing war in that single line hits the bulk of profits), a de-rating of the 4.40x P/B toward the 3.29x low end of its historical range, and consensus EPS being cut from $16.04 toward the $13.75 low estimate. This Hold would upgrade to Buy if the Q4 combined ratio demonstrates Q3 was a plateau rather than a downtrend, or if the price pulls back toward the $210-213 support that has held since August (roughly -7%) while margins stabilize; it would downgrade to Sell if net margin breaks below the 10.97% Q3 level or revenue growth turns negative. On balance the stock is fairly valued relative to its own history and at a premium to peers on book — a reasonable price for a superior franchise, but not a discount.
Sign up to view all
PGR 12-Month Price Forecast
Progressive is a superior franchise — 37.29% ROE, $15.22 billion of trailing FCF, a $94 billion float, and 0.227 debt-to-equity — trading at a fair-to-full price after a strong run. The valuation is genuinely two-sided: 11.81x trailing earnings and a 0.35 PEG look cheap, but the 14.03x forward multiple above the trailing one means the market has already discounted margin normalization, and the +1.7% implied upside leaves no margin of safety. The decisive variable over the next twelve months is whether Q3's margin compression is a plateau or the start of a downtrend; the 2.98% revenue growth and the drop in net margin from 14.02% to 10.97% argue the cycle has turned, while the rising investment income from the float and the low 0.204 beta argue for resilience. I would upgrade to bullish if Q4 confirms a combined-ratio floor and the stock holds the $210-213 support, and downgrade to bearish if net margin breaks below 10.97% or consensus EPS is cut toward $13.75. With a 50% base-case probability centered on the $231.71 average target, the risk/reward is balanced rather than compelling in either direction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Progressive Corporation's 12-month outlook, with a consensus price target around $232.38 and implied upside of +2.1% versus the current price.
Average Target
$232.38
25 analysts
Implied Upside
+2.1%
vs. current price
Analyst Count
25
covering this stock
Price Range
$196 - $262
Analyst target range
Coverage is broad with 21 analysts, but sentiment is decidedly mixed: 8 Buy, 15 Hold, and 2 Sell, a distribution that leans neutral-to-cautious despite the stock's strong recent performance. The average target price of $231.71 implies just +1.7% upside from the current $227.77, essentially signaling that the sell-side views the stock as fairly valued after its run. Consensus EPS estimates of $16.04 (range $13.75-$17.05) on revenue of roughly $96.7 billion frame a business expected to earn solidly but with limited re-rating potential, and the neutral consensus is consistent with the forward PE exceeding the trailing — analysts are not modeling an earnings rebound.
The target range of $196.00 to $262.00 is wide, spanning -13.9% downside to +15.0% upside, which signals genuine disagreement about the margin trajectory rather than uniform conviction. The high target of $262 likely assumes underwriting margins hold near current levels, investment income from the growing float accelerates, and the stock re-rates toward the upper end of its historical P/B band; the low target of $196 prices in continued premium deceleration, competitive pricing pressure in auto, and margin compression toward mid-cycle levels. Institutional actions show a modest positive drift — Keefe, Bruyette & Woods upgraded to Outperform from Market Perform in August 2026 and reiterated, Barclays maintains Overweight, while Wells Fargo remains Underweight and UBS, Mizuho, and JP Morgan stay Neutral — a pattern of stable-to-slightly-improving ratings with persistent bears on valuation. The wide spread and heavy Hold count imply the stock is a show-me story: further upside requires evidence that Q3's margin compression is a plateau rather than the start of a downtrend.
Bulls vs Bears: PGR Investment Factors
The bull case rests on a genuinely superior franchise — 37.29% ROE, $15.22 billion of trailing FCF, a $94 billion float generating rising investment income, and a trailing PE of 11.81x near the low end of its historical band. The bear case rests on the direction of travel: revenue growth of just 2.98%, net margin down from 14.02% in Q2 to 10.97% in Q3, a forward PE above the trailing one, and an analyst consensus target implying only +1.7% upside with 15 of 21 ratings at Hold. On balance the evidence is roughly balanced but tilts slightly bearish near-term, because the margin trajectory is deteriorating faster than the valuation is cheapening and the sell-side has already priced the quality. The single most important tension is whether Q3's margin compression is a plateau or the start of a downtrend — if the combined ratio stabilizes, the 11.81x trailing PE and 0.35 PEG look cheap and the stock re-rates toward the $262 high target; if margins keep sliding toward mid-cycle, the forward-earnings discount is justified and the $196 low target comes into play.
Bullish
- Exceptional ROE justifies book premium: Trailing ROE of 37.29% and ROA of 7.53% are far above the high-single-to-low-double-digit norms for large-cap P&C carriers, which is why the 4.40x P/B is defensible versus the ~1.5-2.0x typical peer multiple. Even after Q3 margin compression, the franchise still earns returns roughly 3-4x the sector's cost of equity spread.
- Trailing PE near multi-year low: At 11.81x trailing earnings, PGR sits near the bottom of a historical band that ranged from the high-teens to 58x in Q2 2023 and 138x in Q3 2022. The market is already pricing normalized rather than peak earnings, leaving re-rating room if underwriting proves more resilient than feared.
- Fortress balance sheet and cash generation: Debt-to-equity of just 0.227, interest coverage above 37x, and trailing free cash flow of $15.22 billion (including $4.40 billion in Q3 alone) mean the company funds growth internally. It still returned $7.97 billion via a Q1 special dividend plus $471 million of Q3 buybacks while growing the investment portfolio.
- Float approaching $94B powers investment income: The growing float is a second earnings engine independent of underwriting, and higher rates on that portfolio provide a structural offset as premium growth decelerates to 2.98% YoY. This is the underappreciated half of the story that supports earnings even in a softer pricing cycle.
Bearish
- Forward PE exceeds trailing, earnings decline priced: The unusual inversion of 14.03x forward versus 11.81x trailing PE means the market explicitly expects earnings to fall from the current run-rate as underwriting margins normalize. Consensus EPS of $16.04 against a $227.77 price leaves little room for disappointment.
- Revenue growth decelerating sharply: Q3 2026 revenue of $23.18 billion grew only 2.98% YoY, and sequentially revenue fell from Q2's $23.62 billion. The rate-increase tailwind that drove the multi-year margin cycle is rolling off, shifting the thesis from growth to margin defense.
- Margin compression already visible: Q3 net margin fell to 10.97% from Q2's 14.02% and Q1's 12.71%, while operating margin dropped to 13.96% from 17.82%. The direction of travel is normalization, and the implied Q3 combined ratio reflects a clear step down from 2025's exceptional levels.
- Analysts see essentially no upside: The average target of $231.71 implies just +1.7% from $227.77, with 15 of 21 analysts at Hold and 2 at Sell. The $196 low target implies -13.9% downside, and the heavy Hold count makes this a show-me story requiring proof that Q3 is a plateau, not a downtrend.
PGR Technical Analysis
Progressive is in a sustained but choppy uptrend: the stock is up 8.66% over the past year and 17.41% over six months, and at $227.77 it sits at roughly 74% of its 52-week range of $189.20 to $241.02, about 5.5% below the high. That positioning signals healthy momentum rather than overextension — the stock is neither pinned at highs nor broken down — and the 22.51% max drawdown over the period confirms this has been a volatile advance rather than a straight line. Notably, the 8.66% one-year gain slightly trails SPY's 9.59%, a relative strength of -0.93%, so the long-term trend is positive in absolute terms but only market-performant over twelve months.
Short-term momentum has decisively re-accelerated and diverged positively from the flat one-year trend: the stock is up 6.37% over one month and 5.78% over three months, versus SPY at -4.99% and -4.91% respectively, producing relative strength of +11.36% (1-month) and +10.69% (3-month). This is a meaningful divergence — the six-month relative strength of +17.95% shows PGR has been a standout defensive compounder while the broad market sold off, consistent with its very low beta of 0.204. The most recent session, however, saw a 2.32% pullback from $233.18 to $227.77, suggesting some profit-taking after the stock probed the $234-235 zone; volume of roughly 2.73 million shares and a short ratio of 2.15 indicate no meaningful bearish positioning building.
Key technical levels are well defined: support sits at the 52-week low of $189.20, roughly 17% below the current price, with intermediate support around the $210-213 area that has repeatedly held since August. Resistance is the 52-week high of $241.02, about 5.8% above the current price; a breakout above that level would confirm the uptrend's resumption and likely trigger momentum buying, while a breakdown below $210 would signal a failed breakout and put the $189 low in play. The beta of 0.204 is the critical risk-management input — the stock moves at roughly one-fifth the market's volatility, making it a defensive ballast position, but it also means upside participation in broad rallies is structurally limited and position sizing can be larger for equivalent risk budget.
Beta
0.20
0.20x market volatility
Max Drawdown
-21.9%
Largest decline past year
52-Week Range
$189-$241
Price range past year
Annual Return
+4.7%
Cumulative gain past year
| Period | PGR Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | -3.3% |
| 3m | +7.1% | -2.3% |
| 6m | +16.1% | +1.4% |
| 1y | +4.7% | +12.2% |
| ytd | +7.3% | +10.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PGR Fundamental Analysis
Revenue growth has decelerated sharply even as the top line reaches record levels: Q3 2026 revenue of $23.18 billion grew just 2.98% year over year from $22.51 billion, a marked slowdown from the double-digit pace of prior years, and sequential revenue actually declined from Q2's $23.62 billion. The multi-quarter trend confirms normalization — Q1 2026 was $22.18 billion, Q2 $23.62 billion, Q3 $23.18 billion — with personal lines at $19.35 billion and commercial lines at $2.83 billion dominating the mix. The deceleration reflects the intended consequence of years of rate increases now rolling off; the investment case shifts from growth-driven to margin-and-float-driven, and the key question is whether unit growth in policies in force can offset moderating premium per policy.
Profitability remains robust but is compressing off peak levels: Q3 2026 net income was $2.54 billion with a net margin of 10.97%, down from Q2's $3.31 billion and 14.02% margin and Q1's $2.82 billion and 12.71% margin, while operating margin fell to 13.96% from 17.82% in Q2. The Q3 combined ratio implied by the data (costs of $19.95 billion against $23.18 billion revenue) reflects still-strong underwriting but a clear step down from the exceptional 2025 levels, when Q2 2025 net margin hit 14.44%. Trailing ROE of 37.29% and ROA of 7.53% remain exceptional for a P&C insurer, and the 16.23% operating margin and 29.47% gross margin are consistent with a best-in-class underwriter, but the direction of travel is margin normalization as pricing softens.
Financial health is a core strength: debt-to-equity is just 0.227, interest coverage exceeds 37x, and trailing free cash flow is $15.22 billion, with quarterly FCF of $4.40 billion in Q3, $3.47 billion in Q2, and $4.30 billion in Q1 — more than enough to fund growth internally. The company returned capital aggressively, including $7.97 billion of dividends paid in Q1 2026 (a special dividend) plus $471 million of buybacks in Q3, while still growing the investment portfolio. The one blemish is liquidity optics — a current ratio of 0.586 reflects the insurer's investment-heavy balance sheet rather than distress — and the low cash balance of $156 million is normal for an insurer that holds float in invested assets. Overall, PGR's balance sheet carries minimal financial risk and its cash generation is a durable competitive asset.
Quarterly Revenue
$23.2B
2026-09
Revenue YoY Growth
+3.0%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$15.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PGR Overvalued?
Because net income is solidly positive ($2.54 billion in Q3 alone), the PE ratio is the appropriate primary metric. PGR trades at 11.81x trailing earnings and 14.03x forward earnings — an unusual inversion where the forward multiple exceeds the trailing, implying the market expects earnings to decline from the current elevated run-rate as underwriting margins normalize. That gap is the single most important valuation signal in the data: investors are paying up on trailing results but the forward curve already discounts margin compression, and the PEG ratio of 0.35 suggests the stock is cheap relative to growth if earnings hold.
Against the broader P&C insurance sector, PGR's 11.81x trailing PE and 1.52x PS look inexpensive in absolute terms, but the comparison must be adjusted for its premium franchise: the 4.40x price-to-book is well above the ~1.5-2.0x typical for large-cap P&C carriers, reflecting PGR's 37.29% ROE versus the sector's high-single-to-low-double-digit norms. The 9.47x EV/EBITDA and 1.51x EV/Sales are moderate, while the 2.15% dividend yield and 25.4% payout ratio are modest. The premium on book value is justified by the ROE spread, but the discount on earnings reflects the cyclical peak — the market is pricing PGR as a high-quality business at a mid-cycle earnings level rather than extrapolating peak underwriting profits.
Historically, PGR's PE has ranged from the high-teens to over 50x during the 2022-2023 underwriting downturn (58x in Q2 2023, 138x in Q3 2022 when earnings collapsed), and its price-to-book has ranged from roughly 3.3x to 5.7x. At 11.81x trailing PE, the stock is near the low end of its multi-year earnings multiple band, while the 4.40x P/B sits in the middle of its historical range (3.29x in Q4 2021 to 5.73x in Q1 2025). The read-through is that the market is pricing normalized rather than peak earnings — a reasonable stance given the margin compression visible in Q3 — leaving upside if underwriting proves more resilient than feared, but limited multiple expansion potential if margins continue to fade.
PE
11.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~23x
vs. Industry Avg
12.7x
Industry PE ~12.7x*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the underwriting cycle rather than the balance sheet. Net margin fell from 14.02% in Q2 2026 to 10.97% in Q3, operating margin from 17.82% to 13.96%, and revenue grew only 2.98% YoY with a sequential decline from $23.62 billion to $23.18 billion — a clear signal that the rate-driven margin peak has passed. Earnings are highly concentrated in personal auto ($19.35 billion of Q3's $23.18 billion revenue), so a competitive pricing war in that single line would hit the bulk of profits directly. The current ratio of 0.586 and $156 million cash balance are normal for an insurer holding float in invested assets, but they mean liquidity depends on the investment portfolio, and the $7.97 billion special dividend in Q1 2026 shows capital return is variable rather than a reliable income stream. Debt-to-equity of 0.227 and interest coverage above 37x keep solvency risk low, so the real financial risk is earnings volatility, not leverage.
Market and competitive risks are dominated by valuation and cyclical positioning. At 4.40x book versus the ~1.5-2.0x typical for large-cap P&C carriers, PGR carries a premium that depends on sustaining its ROE advantage; any narrowing of the loss-ratio gap to peers would compress that multiple toward the 3.29x low end of its historical range. The forward PE of 14.03x exceeding the trailing 11.81x means the market has already discounted margin compression, so the risk is not overvaluation on earnings but a further leg down in the earnings base itself. Beta of 0.204 limits market-correlation risk but also caps upside participation, and the stock's 22.51% max drawdown over the period shows it is not immune to sharp corrections. Recent coverage highlights the debate: Motley Fool notes the high dividend yield is unreliable for income investors, while other commentary frames the $94 billion float and higher rates as the offsetting earnings driver.
Worst-case scenario: auto pricing competition intensifies, personal auto combined ratios drift toward mid-cycle, and the forward-earnings discount proves correct rather than conservative. In that chain, Q3's 10.97% net margin keeps compressing toward the 11.6-12.6% levels seen in 2025's earlier quarters and below, consensus EPS of $16.04 gets cut toward the $13.75 low estimate, and the stock de-rates toward the $196 analyst low target — about -13.9% from $227.77. A fuller breakdown below the $210-213 support that has held since August would put the 52-week low of $189.20 in play, roughly -17% from the current price, consistent with the 22.51% max drawdown already experienced. Investors should size positions assuming a realistic 14-17% downside in the adverse case, cushioned somewhat by the 2.15% dividend yield and the low-beta defensive profile.
FAQ
The most severe risk is earnings normalization in personal auto, which at $19.35 billion of Q3's $23.18 billion revenue is the profit engine: net margin already fell from 14.02% in Q2 to 10.97% in Q3 and operating margin from 17.82% to 13.96%, and a competitive pricing war in that single line would hit the bulk of profits. Second is valuation de-rating: at 4.40x book versus ~1.5-2.0x for peers, a move toward the 3.29x low end of PGR's historical range would compound any earnings decline, and the forward PE above the trailing one shows the market has already priced compression. Third is estimate risk — consensus EPS of $16.04 could be cut toward the $13.75 low estimate, which would likely trigger the downgrades that 15 Hold-rated analysts are already positioned for. Fourth, company-specific capital-return variability: the $7.97 billion Q1 2026 special dividend means the 2.15% yield is not a reliable income stream, and the low 0.586 current ratio and $156 million cash balance, while normal for an insurer, leave liquidity dependent on the investment portfolio.
The 12-month forecast is centered on the base case, assigned a 50% probability, with a $220-$235 target range anchored on the $231.71 analyst average and supported by the 11.81x trailing PE and 4.40x P/B, assuming consensus EPS of $16.04 is broadly met and net margin stabilizes in the 10-12% range. The bull case carries 25% probability and a $241.02-$262 range, requiring the Q4 combined ratio to confirm a margin floor plus accelerating investment income on the $94 billion float and continued buybacks. The bear case carries 25% probability and a $189.20-$196 range, driven by auto pricing competition, net margin breaking below 10.97%, and EPS cuts toward $13.75 that de-rate the stock toward the analyst low target and the 52-week low. The most likely outcome is the base case: roughly flat to slightly lower earnings with the stock range-bound, since the market has already discounted margin normalization and the sell-side sees only +1.7% upside.
PGR looks fairly valued on earnings and modestly rich on book. The 11.81x trailing PE sits near the low end of a historical band that ran from the high-teens to 58x in Q2 2023, and the 0.35 PEG and 1.52x PS look inexpensive in absolute terms — but the 14.03x forward PE exceeding the trailing multiple is an unusual inversion that signals the market expects earnings to decline as underwriting margins normalize. On book, the 4.40x P/B is well above the roughly 1.5-2.0x typical for large-cap P&C peers, though it is defensible against a 37.29% ROE and sits mid-range versus PGR's own 3.29x-5.73x history. The market is therefore paying a premium for franchise quality while discounting the earnings base to a mid-cycle level rather than extrapolating peak underwriting profits. That implies limited multiple expansion unless margins prove more resilient than feared, and meaningful de-rating risk toward 3.29x book if the ROE premium narrows.
From a pure risk/reward standpoint, PGR is a reasonable but not compelling buy at $227.77. The upside to the $231.71 analyst average target is only about +1.7%, while the $196 low target implies roughly -13.9% downside, so the near-term asymmetry is unfavorable even though the franchise quality is exceptional (37.29% ROE, $15.22 billion trailing FCF, 0.227 debt-to-equity). The biggest downside risk is a continued slide in personal auto underwriting margins — personal lines are $19.35 billion of Q3's $23.18 billion revenue — which would validate the forward PE of 14.03x exceeding the trailing 11.81x and pull the stock toward the $210-213 support or the $189.20 52-week low. It is a good buy for long-horizon, low-volatility investors who want defensive ballast (beta 0.204, 2.15% yield) and are willing to accumulate on weakness toward $210 or below, and for those who believe Q3's margin compression is a plateau rather than a downtrend. It is a poor buy for investors seeking near-term upside or income reliability, given the special-dividend-driven payout and the heavy 15-of-21 Hold consensus.
PGR is structurally better suited to long-term holding than short-term trading. Its beta of 0.204 means it moves at roughly one-fifth the market's volatility, which limits the price swings that short-term traders rely on, and its 8.66% one-year return slightly trailed SPY's 9.59% even as it outperformed by +17.95% over six months — a pattern of defensive compounding rather than momentum. The growth stage is mature: revenue grew just 2.98% YoY in Q3 with sequential decline from $23.62 billion to $23.18 billion, so the long-term return case rests on ROE durability (37.29%), float-driven investment income, and buybacks rather than top-line expansion. Earnings visibility is moderate — the wide $196-$262 analyst target range and 15 Hold ratings reflect genuine uncertainty about the margin trajectory — and the 2.15% dividend yield is unreliable for income given the special-dividend structure. A minimum holding period of 18-24 months is appropriate, allowing time for the underwriting cycle to find a floor and for investment income to compound; short-term traders should instead watch the $210-213 support and $241.02 resistance as defined risk levels.